Detection of Vaccine Adverse Events Before Package Insert Revisions Using a Japanese Spontaneous Reporting System.
Japanese Adverse Drug Event Report database
disproportionality analysis
drug safety
pharmacovigilance
vaccine
Journal
Journal of clinical pharmacology
ISSN: 1552-4604
Titre abrégé: J Clin Pharmacol
Pays: England
ID NLM: 0366372
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
24
02
2023
accepted:
06
04
2023
medline:
11
7
2023
pubmed:
13
4
2023
entrez:
12
4
2023
Statut:
ppublish
Résumé
The usefulness of disproportionality analysis for the pharmacovigilance of vaccines in the Japanese Adverse Drug Event Report (JADER) database is yet to be proven. This study aimed to verify whether significant disproportionality could be detected before adding new vaccine adverse event information to package inserts. Information on package insert revisions related to vaccine adverse drug events from January 2013 to March 2023 was extracted from the Pharmaceuticals and Medical Devices Agency website. This period was set as the maximum period for which early disproportionalities could be detected by the latest JADER database (April 2004 to December 2022). From JADER data, 15 revision histories (10 types of vaccines) of package inserts were identified, and 823,662 cases were obtained. Of the 15, 12 (80%) adverse events were identified as significant disproportionalities before package insert revisions were made. Nine of the 15 (60%) events were identified as significant disproportionalities earlier than at least 12 months. These findings suggest that the JADER database may detect vaccine adverse events earlier than package insert revisions, indicating its usefulness for the safety surveillance of vaccines.
Substances chimiques
Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
903-908Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2023 The Authors. The Journal of Clinical Pharmacology published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.
Références
Dixon MG, Reef SE, Zimmerman LA, Grant GB. Past as prologue-use of rubella vaccination program lessons to inform COVID-19 vaccination. Emerg Infect Dis. 2022;28(13):S225-S231.
Chiou H, Voegeli C, Wilhelm E, Kolis J, Brookmeyer K, Prybylski D. The future of infodemic surveillance as public health surveillance. Emerg Infect Dis. 2022;28(13):S121-S128.
The Centers for Disease Control and Prevention (CDC), the US Food and Drug Administration (FDA). Vaccine Adverse Event Reporting System. Accessed June 10, 2022. https://vaers.hhs.gov/index.html
Shimabukuro TT, Nguyen M, Martin D, DeStefano F. Safety monitoring in the vaccine adverse event reporting system (VAERS). Vaccine. 2015;33(36):4398-4405.
Asatryan A, Pool V, Chen RT, et al. Live attenuated measles and mumps viral strain-containing vaccines and hearing loss: vaccine adverse event reporting system (VAERS), United States, 1990-2003. Vaccine. 2008;26:1166-1172.
Haber P, DeStefano F, Angulo FJ, et al. Guillain-Barré syndrome following influenza vaccination. JAMA. 2004;292(20):2478-2481.
Yamaguchi T, Iwagami M, Ishiguro C, et al. Safety monitoring of COVID-19 vaccines in Japan. Lancet Reg Health West Pac. 2022;23:100442.
Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13(8):519-523.
Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483-486.